ScripDiversified major Japanese foods firm Ajinomoto Co., Inc. is to acquire the US gene therapy-focused contract development and manufacturing organization (CDMO) Forge Biologics for approximately $554m
Pink SheetThe waning of the COVID-19 pandemic was reflected in three FDA decisions issued last week for applications that had been under review long past their user fee goal dates because manufacturing inspecti
Pink SheetA trio of novel cancer agent applications announced last week illustrates the breadth of oncology R&D, from targeted kinase inhibitors ( Taiho Pharmaceutical Co. Ltd. ’s futibatinib) to antibody-drug
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Partnerships With Evotec, Anima, Geneva